Company name
Switchkine SA
Company profile
Switchkine is a preclinical-stage company engineering cytokines&ligands in a proprietary Duokine format to enable a multi-target approach to chronic inflammation. The Duokine platform combines two modules - a receptor ligand and a monomeric IL-10, engineered to retain activity in acidic environments-a hallmark of chronic inflammation. By targeting both lymphoid and myeloid drivers of disease, Duokines aim to restore homeostasis beyond the limits of single-target therapies.
Date, time and room information
Monday, May 4, 15:00 - 15:15, room Singapore
Category
Emerging biotech company
Title of the presentation
RETHINKING CHRONIC INFLAMMATION TREATMENT WITH A TAILORED MULTI-TARGET APPROACH
Speaker information
| Name | Position | Institution |
|---|---|---|
| Madiha Derouazi | CEO | Switchkine SA |
